{"nctId":"NCT00516503","briefTitle":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","startDateStruct":{"date":"2008-02"},"conditions":["Chronic Myeloproliferative Disorders","Leukemia","Lymphoma","Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Neoplasms","Neurotoxicity","Pain","Unspecified Adult Solid Tumor, Protocol Specific"],"count":208,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Drug: baclofen/amitriptyline/ketamine gel"]},{"label":"Arm II","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"baclofen/amitriptyline/ketamine gel","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\\>\n\n* Diagnosis of cancer\\>\n* Received or currently receiving neurotoxic chemotherapy including, but not limited to, taxanes (e.g., paclitaxel or docetaxel); platinum-based compounds (e.g., carboplatin, cisplatin, or oxaliplatin); vinca alkaloids (e.g., vincristine or vinblastine); or other neurotoxic chemotherapy agents (e.g., bortezomib, lenalidomide, or thalidomide)\\>\n* Must have pain or symptoms of peripheral neuropathy attributable to chemotherapy for ≥ 1 month\\>\n\n  * Neuropathy is limited to either hands and/or feet where gel can be applied\\>\n  * Neuropathic pain score of ≥ 4 out of 10 on the numbness/tingling/pain numeric analogue scale\\>\n* No pre-existing or history of peripheral neuropathy due to any cause other than chemotherapy (e.g., diabetes, alcohol, toxin, heredity)\\> PATIENT CHARACTERISTICS:\\>\n* ECOG performance status 0-2\\>\n* Life expectancy ≥ 4 months\\>\n* Creatinine ≤ 1.5 times upper limit of normal\\>\n* Not pregnant or nursing\\>\n* No ability to bear children defined by 1 of the criteria:\\>\n\n  * Menopausal (12 months and no menstrual period if natural menopause)\\>\n  * Underwent a hysterectomy and/or oophorectomy\\>\n  * Permanent surgical sterilization (tubal ligation)\\>\n* Fertile patients must use effective contraception\\>\n* Able to complete questionnaires independently or with assistance\\>\n* Able to sign informed consent and understand the nature of a placebo-controlled trial\\>\n* No history of an allergic reaction to baclofen, amitriptyline hydrochloride, and/or ketamine\\>\n* No diagnosis of any New York Heart Association class I-IV congestive heart failure\\>\n* No diagnosis of coronary artery disease including, but not limited to, myocardial infarction, within the past 5 years\\>\n* No other medical condition that, in the opinion of the treating physician or allied health professional, would make this clinical trial unreasonably hazardous for the patient\\>\n* No skin abnormalities at the intended application sites (hands and feet) of study gel (i.e., skin breakdown)\\> PRIOR CONCURRENT THERAPY:\\>\n* See Disease Characteristics\\>\n* More than 30 days since prior anticonvulsants, tricyclic antidepressants, monoamine oxidase inhibitor, or other neuropathic pain medication (e.g., carbamazepine, phenytoin, valproic acid, gabapentin, lamotrigine, topical lidocaine patch or gel, capsaicin cream, or amifostine)\\>\n\n  \\- Patients treated with any of these agents for peripheral neuropathy for ≤ 1 week during the past 30 days are eligible provided they are no longer taking the agent\\>\n* More than 5 years since prior percutaneous transluminal coronary angioplasty or coronary artery bypass graft\\>\n\n  \\- Prior heart valve replacement surgery allowed provided patient has fully recovered from the surgery\\>\n* No concurrent use of study agents other than as specified in the trial\\>","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Sensory Neuropathy as Measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life [QLQ] - Chemo-induced Peripheral Neuropathy [CIPN20]","description":"The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The primary analysis was the change in sensory neuropathy subscale of the CIPN-20 from baseline to week 4. The area under the curve (AUC) from baseline to week 4 was calculated for each patient's sensory neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":"16.22"},{"groupId":"OG001","value":"60.9","spread":"17.9"}]}]}]},{"type":"SECONDARY","title":"Motor Neuropathy as Measured by the EORTC QLQ-CIPN20 at Baseline and Week 4","description":"The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The secondary analysis was to compare changes from baseline at 4 weeks for the motor neuropathy subscale of the CIPN-20. To analyze this endpoint, the area under the curve (AUC) from baseline to week 4 was calculated for each patient's motor neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":"17.15"},{"groupId":"OG001","value":"70.1","spread":"19.48"}]}]}]},{"type":"SECONDARY","title":"Autonomic Symptoms and Functioning as Measured by the EORTC QLQ-CIPN20 at Baseline and Week 4","description":"The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The secondary analysis was to compare changes from baseline at 4 weeks for the autonomic neuropathy subscale of the CIPN-20. To analyze this endpoint, the area under the curve (AUC) from baseline to week 4 was calculated for each patient's motor neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":"15.47"},{"groupId":"OG001","value":"86.8","spread":"15.03"}]}]}]},{"type":"SECONDARY","title":"Mood States and Total Mood Disturbance as Measured by the Profile of Mood States (POMS)","description":"Each mood scale (0 - 100, higher is better mood) will be analyzed as an endpoint along with the total mood disturbance score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":"17.09"},{"groupId":"OG001","value":"83.0","spread":"15.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":"18.42"},{"groupId":"OG001","value":"33.0","spread":"19.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.8","spread":"14.48"},{"groupId":"OG001","value":"87.7","spread":"12.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":"17.58"},{"groupId":"OG001","value":"77.9","spread":"11.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":"16.09"},{"groupId":"OG001","value":"85.8","spread":"15.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":"21.69"},{"groupId":"OG001","value":"63.6","spread":"22.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.5","spread":"13.27"},{"groupId":"OG001","value":"71.8","spread":"13.14"}]}]}]},{"type":"SECONDARY","title":"Pain Severity and Interference as Measured by the Brief Pain Inventory (BPI) at Baseline and Week 4","description":"Pain severity, defined by the four items addressing worst, least, and average pain and pain right now as measured by the BPI will be analyzed identical to the primary endpoint. Additionally, total pain interference as measured by the BPI will be transformed onto a 0-100 ( higher is less pain) point scale. The area under the curve (AUC) from baseline to week 4 was calculated for each patient's score. The average AUC for the placebo arm and the topical amitriptyline HCl/ baclofen/ ketamine arm are reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":"25.48"},{"groupId":"OG001","value":"58.7","spread":"27.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.0","spread":"20.28"},{"groupId":"OG001","value":"77.3","spread":"22.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.4","spread":"21.99"},{"groupId":"OG001","value":"65.4","spread":"24.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":"20.16"},{"groupId":"OG001","value":"77.3","spread":"21.16"}]}]}]},{"type":"SECONDARY","title":"Numbness, Tingling, and Pain as Measured by the Peripheral Neuropathy Questionnaire at Baseline and Weekly for 4 Weeks","description":"The Peripheral Neuropathy Questionnaire was used to analyze this endpoint. Patient neuropathy symptoms were scored on a 0 - 100 scale (higher score represents less symptomatic). The area under the curve (AUC) from baseline to week 4 was calculated for each patient's score. The average AUC for the placebo arm and the topical amitriptyline HCl/ baclofen/ ketamine arm are reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"172.6","spread":"82.09"},{"groupId":"OG001","value":"175.7","spread":"85.38"}]}]}]},{"type":"SECONDARY","title":"Adverse Event Profile of Topical Amitriptyline HCl/ Baclofen/Ketamine > Frequency and Severity of Adverse Events Reported by the Patient in the > Symptom Experience Diary and Evaluated Through Clinical Assessment by NCI CTCAE v3.0","description":"Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":101},"commonTop":["Constipation","Dry mouth","Hand-and-foot syndrome","Confusion","Depressed level of consciousness"]}}}